Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Peritoneal carcinomatosis : cytoreductive surgery and HIPEC--overview and basics

Brücher, Björn L D M ; Piso, Pompiliu ; Verwaal, Vic LU ; Esquivel, Jesus ; Derraco, Marcello ; Yonemura, Yutaka ; Gonzalez-Moreno, Santiago ; Pelz, Jörg ; Königsrainer, Alfred and Ströhlein, Michael , et al. (2012) In Cancer Investigation 30(3). p.24-209
Abstract

Tumor involvement of the peritoneum-peritoneal carcinomatosis-is a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the... (More)

Tumor involvement of the peritoneum-peritoneal carcinomatosis-is a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the substantial logistic effort and the extent of the surgery involved, this treatment approach represents a major challenge both for patients and for surgical oncologists, as well as for the members of the overall interdisciplinary structure required, which includes oncology, anesthesiology and intensive care, psycho-oncology, and patient management. The surgical procedures alone may take 8-14 hr. The present paper provides an overview of the basis for the approach and the use of specialized classifications and quantitative prognostic indicators.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antineoplastic Agents/administration & dosage, Combined Modality Therapy, Humans, Hyperthermia, Induced/methods, Injections, Intraperitoneal, Laparoscopy, Peritoneal Neoplasms/mortality, Peritoneum/surgery, Prognosis
in
Cancer Investigation
volume
30
issue
3
pages
24 - 209
publisher
Informa Healthcare
external identifiers
  • scopus:84857586698
  • pmid:22360361
ISSN
0735-7907
DOI
10.3109/07357907.2012.654871
language
English
LU publication?
no
id
41bf1fb9-45b2-49f2-b619-3665bef5a4b7
date added to LUP
2022-04-12 09:48:09
date last changed
2024-03-07 22:54:38
@article{41bf1fb9-45b2-49f2-b619-3665bef5a4b7,
  abstract     = {{<p>Tumor involvement of the peritoneum-peritoneal carcinomatosis-is a heterogeneous form of cancer that had been generally regarded as a sign of systemic tumor disease and as a terminal condition. The multimodal treatment approach for patients with peritoneal carcinomatosis, which had been conceived and developed, consists of what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Depending on the tumor mass as assessed intraoperatively and the histopathological differentiation, patients who undergo cytoreductive surgery and HIPEC have a significant survival benefit. Mean increases in the survival period ranging from six months to up to four years have now been reported. In view of the substantial logistic effort and the extent of the surgery involved, this treatment approach represents a major challenge both for patients and for surgical oncologists, as well as for the members of the overall interdisciplinary structure required, which includes oncology, anesthesiology and intensive care, psycho-oncology, and patient management. The surgical procedures alone may take 8-14 hr. The present paper provides an overview of the basis for the approach and the use of specialized classifications and quantitative prognostic indicators.</p>}},
  author       = {{Brücher, Björn L D M and Piso, Pompiliu and Verwaal, Vic and Esquivel, Jesus and Derraco, Marcello and Yonemura, Yutaka and Gonzalez-Moreno, Santiago and Pelz, Jörg and Königsrainer, Alfred and Ströhlein, Michael and Levine, Edward A and Morris, David and Bartlett, David and Glehen, Olivier and Garofalo, Alfredo and Nissan, Aviram}},
  issn         = {{0735-7907}},
  keywords     = {{Antineoplastic Agents/administration & dosage; Combined Modality Therapy; Humans; Hyperthermia, Induced/methods; Injections, Intraperitoneal; Laparoscopy; Peritoneal Neoplasms/mortality; Peritoneum/surgery; Prognosis}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{24--209}},
  publisher    = {{Informa Healthcare}},
  series       = {{Cancer Investigation}},
  title        = {{Peritoneal carcinomatosis : cytoreductive surgery and HIPEC--overview and basics}},
  url          = {{http://dx.doi.org/10.3109/07357907.2012.654871}},
  doi          = {{10.3109/07357907.2012.654871}},
  volume       = {{30}},
  year         = {{2012}},
}